Renew Biopharma CEO Michael Mendez to Speak at SynBioBeta 2018

SAN FRANCISCO -- (BUSINESS WIRE) -- Michael Mendez, Renew Biopharma founder and CEO, and long-time biotech industry pioneer, will speak tomorrow about his company’s quest to look beyond the Cannabis plant to discover and develop “a new world of novel therapeutics” at SynBioBeta 2018.

Changing the Course Of Pain Management. Opioid Crisis Has Cos. Looking to Develop Safer Treatments

San Diego — In 2014, Heron Therapeutics took notice of the role of postoperative pain in opioid addiction. So, the company dusted off a shelved drug program. Heron is among the San Diego pharma and biotechs rushing to market with alternatives to opioids, dependence on which mushroomed into a national health epidemic. Their treatments aim to prevent dependence, overdoses and side effects.

Renew Biopharma Launches Pre-Clinical Drug Discovery Program with Indiana University Bloomington’s Gill Center for Biomolecular Science Using Cannabinoids Grown in Microalgae

SAN DIEGO -- In a collaboration that could lead to a new class of drugs to replace opioids and help fight the national opioid epidemic, Renew Biopharma today announced it is collaborating with Ken Mackie from the Indiana University (Bloomington) Gill Center for Biomolecular Science to help screen and develop human therapeutics using Renew’s natural and novel cannabinoid molecules in a pre-clinical drug discovery program.

Next Gen Cannabinoids for Clinical Neurology

Contact Us

General Inquiries: info@renewbiopharma.com

Press Inquiries: press@renewbiopharma.com

Contact Us